Biotech Values

[DewDiligence]

Palforzia peanut-allergy drug—>commercial bust, says Nestle:

https://www.wsj.com/articles/nestle-may-shed-peanut-allergy-treatment-as-sales-disappoint-11669724713

Nestlé SA said Tuesday it would explore strategic options for the treatment, effectively putting the drug up for sale, following lower-than-expected demand from doctors and patients. The move comes just two years after the packaged-food giant agreed to buy the developer of the drug, called Palforzia, in a $2.6 billion deal [#msg-157987026].

…[Palforza’s] lackluster performance was likely linked to the laborious treatment process, which involves visits to an allergist every two weeks for four to five months. Because of the risk of anaphylaxis that might require treatment by EpiPen patients must remain under medical supervision for at least one hour after taking the treatment. …allergists weren’t compensated for the extra time required to treat patients with Palforzia and that laws prevented the company from offering any payment to physicians to make up for that.